Amifampridine Phosphate Patent Expiration
Amifampridine Phosphate is Used for treating Lambert-Eaton Myasthenic Syndrome. It was first introduced by Catalyst Pharmaceuticals Inc
Amifampridine Phosphate Patents
Given below is the list of patents protecting Amifampridine Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Firdapse | US10626088 | Determining degradation of 3,4-diaminopyridine | Feb 25, 2037 | Catalyst Pharms |
| Firdapse | US10793893 | Methods of administering 3,4-diaminopyridine | May 26, 2034 | Catalyst Pharms |
| Firdapse | US11060128 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
| Firdapse | US11268128 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
| Firdapse | US11274331 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
| Firdapse | US11274332 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
Amifampridine Phosphate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List